ALBIO Stock Overview
Designs, manufactures, and distributes rapid diagnostic tests in France and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Biosynex SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.30 |
| 52 Week High | €8.97 |
| 52 Week Low | €1.28 |
| Beta | -2.07 |
| 1 Month Change | -53.21% |
| 3 Month Change | -69.79% |
| 1 Year Change | -84.50% |
| 3 Year Change | -94.46% |
| 5 Year Change | -51.64% |
| Change since IPO | -92.78% |
Recent News & Updates
Benign Growth For Biosynex SA (EPA:ALBIO) Underpins Stock's 27% Plummet
Oct 30
Biosynex SA's (EPA:ALBIO) Shares Bounce 28% But Its Business Still Trails The Industry
Aug 16Biosynex SA (EPA:ALBIO) Not Doing Enough For Some Investors As Its Shares Slump 30%
Jun 29Recent updates
Benign Growth For Biosynex SA (EPA:ALBIO) Underpins Stock's 27% Plummet
Oct 30Biosynex SA's (EPA:ALBIO) Shares Bounce 28% But Its Business Still Trails The Industry
Aug 16Biosynex SA (EPA:ALBIO) Not Doing Enough For Some Investors As Its Shares Slump 30%
Jun 29Biosynex SA (EPA:ALBIO) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Mar 12Biosynex SA's (EPA:ALBIO) Shares Not Telling The Full Story
Jan 20Returns On Capital Are Showing Encouraging Signs At Biosynex (EPA:ALBIO)
May 05Investors Shouldn't Overlook Biosynex's (EPA:ALBIO) Impressive Returns On Capital
Dec 01Biosynex (EPA:ALBIO) Could Easily Take On More Debt
Jun 23If You Like EPS Growth Then Check Out Biosynex (EPA:ALBIO) Before It's Too Late
Jul 11Here's Why I Think Biosynex (EPA:ALBIO) Is An Interesting Stock
Apr 06We Think Biosynex (EPA:ALBIO) Can Stay On Top Of Its Debt
Dec 19Shareholder Returns
| ALBIO | FR Medical Equipment | FR Market | |
|---|---|---|---|
| 7D | -20.0% | 0.003% | -1.7% |
| 1Y | -84.5% | 23.6% | -4.8% |
Return vs Industry: ALBIO underperformed the French Medical Equipment industry which returned 23.6% over the past year.
Return vs Market: ALBIO underperformed the French Market which returned -4.8% over the past year.
Price Volatility
| ALBIO volatility | |
|---|---|
| ALBIO Average Weekly Movement | 11.5% |
| Medical Equipment Industry Average Movement | 6.7% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.7% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: ALBIO's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: ALBIO's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 515 | Larry Abensur | www.biosynex.com |
Biosynex SA designs, manufactures, and distributes rapid diagnostic tests in France and internationally. The company offers medical devices for in vitro diagnosis in the form of rapid diagnostic tests, immunoblots, molecular biology, and point of care products for screening, diagnosis, and prevention in the areas of bacteriology, parasitology, mycology, virology, biochemistry and oncology, and women’s health, as well as COVID-19 tests and instruments. It also provides self-tests; self-measurement products, including thermometers, oxymeters, and blood pressure monitors; and oral care and medical aid products.
Biosynex SA Fundamentals Summary
| ALBIO fundamental statistics | |
|---|---|
| Market cap | €13.95m |
| Earnings (TTM) | -€38.48m |
| Revenue (TTM) | €104.07m |
0.1x
P/S Ratio-0.4x
P/E RatioIs ALBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALBIO income statement (TTM) | |
|---|---|
| Revenue | €104.07m |
| Cost of Revenue | €49.01m |
| Gross Profit | €55.06m |
| Other Expenses | €93.54m |
| Earnings | -€38.48m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.58 |
| Gross Margin | 52.91% |
| Net Profit Margin | -36.97% |
| Debt/Equity Ratio | 59.6% |
How did ALBIO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 03:46 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Biosynex SA is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Laure Pédurand | EuroLand Corporate |